What Is GHK-Cu? A Complete Guide to the Copper Tripeptide

GHK-Cu occupies a unique position in the research peptide landscape. It's one of the shortest bioactive peptides in current research use — just three amino acids bound to a single copper ion — yet it modulates expression of over 4,000 human genes (approximately 32% of the human genome). This combination of extreme structural simplicity and unprecedented gene-modulation breadth has made GHK-Cu one of the most extensively studied small peptides in modern biology, with more than five decades of published research and 1,016% year-over-year search growth as of 2026 — the fastest-growing peptide by consumer search interest.

This guide covers what GHK-Cu is, how it was discovered, how it functions mechanistically, and where it fits within the current research peptide landscape. For research groups selecting compounds for skin biology, wound healing, gene expression, or regenerative research designs, understanding GHK-Cu's specific properties — and why they differ fundamentally from receptor-targeted peptides — is essential to matching the compound to the research question.

Our GHK-Cu research peptide is available at ≥99% HPLC purity with mass-spec-verified identity and batch-specific certificates of analysis. Every vial is supplied strictly for laboratory research use only. As of mid-2026, GHK-Cu is investigational — not approved by Health Canada or the FDA for any human therapeutic use — though its presence in topical cosmetic products (as "copper tripeptide-1") has made it one of the most widely accessible peptides in the broader wellness market.

The Core Definition

GHK-Cu is a naturally occurring copper tripeptide consisting of the amino acids glycine-histidine-lysine (in that order) bound to a single copper(II) ion — molecular formula C14H24N6O4Cu, molecular weight approximately 403.9 Da (CAS: 89030-95-5) — with the copper ion tightly held by the peptide structure at a binding constant of log K ≈ 16.4 at physiological pH. The name is derived from the single-letter amino acid code: G (glycine), H (histidine), K (lysine), plus Cu (copper).

The compound exists naturally in human blood plasma, where it's produced through the breakdown of larger collagen proteins during tissue damage. GHK-Cu is also known as copper tripeptide-1 (its cosmetic industry designation) and glycyl-L-histidyl-L-lysine copper. The tripeptide itself (GHK without copper) exists briefly in circulation, but its biological activity depends on copper binding — the copper-bound complex is the active form documented across GHK-Cu research.

Beyond the simple structure, GHK-Cu has three defining characteristics that distinguish it from nearly every other research peptide. First, it operates through dual mechanisms: direct gene expression modulation combined with copper delivery to copper-dependent enzymes throughout the cell. Second, its endogenous concentration in human plasma declines dramatically with age — from approximately 200 ng/mL at age 20 to approximately 80 ng/mL by age 60 — providing a clear biological rationale for replenishment research. Third, its gene expression modulation is unusually broad, affecting approximately 4,000 genes rather than the narrow gene targets of most bioactive compounds.

The Discovery History

GHK-Cu was discovered in 1973 by Dr. Loren Pickart at the University of California, San Francisco, during research investigating why blood plasma from young donors could restore youthful characteristics to aged liver tissue cultures — a serendipitous observation that led to identifying a copper-bound tripeptide as the responsible factor. The discovery launched more than five decades of GHK-Cu research that Pickart himself and hundreds of independent research groups have continued expanding.

Why the discovery mattered

Before GHK-Cu, the concept that a three-amino-acid peptide bound to a metal ion could produce broad biological effects was not part of mainstream biochemistry. Most bioactive peptides were assumed to require larger structures — receptor-binding domains, secondary structural motifs, or complex three-dimensional folding — to produce meaningful cellular effects. Pickart's demonstration that a tripeptide-copper complex could reverse aging-related characteristics in cell cultures opened an entirely new research direction: small metallopeptides as bioactive signaling molecules capable of modulating cellular behavior at low concentrations.

The gene expression revolution

The most significant modern advance in GHK-Cu understanding came in 2014, when Pickart, Vasquez-Soltero, and Margolina used the Broad Institute's Connectivity Map database to analyze GHK's effects on human gene expression. The Connectivity Map tracks how compounds affect gene activity across the human genome, and GHK's results were striking — the tripeptide modulated expression of over 4,000 genes at nanomolar concentrations. Genes associated with DNA repair, antioxidant response, and tissue remodeling were upregulated; genes linked to inflammation, tumor progression, and cellular aging markers were downregulated. Peer-reviewed research on GHK-Cu gene expression is available through PubMed GHK-Cu gene expression research.

Research expansion after discovery

Since the 1973 discovery, GHK-Cu research has expanded substantially across multiple domains. Notable milestones include Kang et al.'s 2009 characterization of GHK-Cu stem cell activation in Archives of Dermatological Research, McCormack et al.'s 2001 documentation of DNA repair and cellular function restoration after radiation damage, Hong et al.'s 2010 identification of GHK-Cu as one of the most potent cancer gene suppressors identified out of 1,309 bioactive compounds tested, and the comprehensive 2018 review by Pickart and Margolina in the International Journal of Molecular Sciences that consolidated the gene expression evidence base. Their 2018 review is available through the International Journal of Molecular Sciences.

How GHK-Cu Works: The Dual-Action Mechanism

GHK-Cu operates through two integrated mechanisms — direct modulation of human gene expression across approximately 4,000 genes (~32% of the human genome), combined with controlled copper delivery to copper-dependent enzymes throughout cellular metabolism. Unlike most bioactive peptides that bind cell-surface receptors, GHK-Cu's activity reflects intrinsic cellular effects rather than receptor-mediated signaling.

Gene expression modulation

The gene modulation mechanism is what distinguishes GHK-Cu from most research peptides. When cells are exposed to GHK-Cu at nanomolar concentrations, expression of thousands of genes shifts in coordinated patterns — genes involved in DNA repair, antioxidant defense, extracellular matrix synthesis, and tissue remodeling are upregulated, while genes involved in inflammatory responses, tumor progression, and cellular senescence markers are downregulated. This isn't the effect of a single receptor binding event triggering a specific signaling cascade; it's a broad transcriptional shift that reshapes cellular behavior across multiple functional programs simultaneously.

Copper delivery

GHK-Cu also functions as a controlled copper carrier. The copper ion is held tightly enough (log K ≈ 16.4) to remain stably bound during circulation and cellular uptake, but the copper is bioavailable to copper-dependent enzymes once GHK-Cu reaches its intracellular targets. Copper is a critical cofactor for numerous enzymes involved in tissue repair, antioxidant defense, and connective tissue synthesis — including lysyl oxidase (essential for collagen and elastin cross-linking), superoxide dismutase (antioxidant enzyme), and cytochrome c oxidase (mitochondrial electron transport). By delivering copper specifically to sites of tissue damage or metabolic activity, GHK-Cu supports these copper-dependent enzymatic systems.

ECM remodeling

The combined gene expression and copper delivery mechanisms drive extracellular matrix (ECM) remodeling effects that characterize much of GHK-Cu's research applications. Published research documents GHK-Cu-driven increases in collagen synthesis by dermal fibroblasts, glycosaminoglycan production (including decorin and dermatan sulfate), elastin cross-linking (through copper-dependent lysyl oxidase), and organized ECM assembly. These effects are particularly prominent in dermal tissue, connective tissue, and wound healing contexts where ECM biology is central to research questions.

Why Age-Related GHK-Cu Decline Matters

Endogenous GHK-Cu concentration in human plasma declines progressively with age — from approximately 200 ng/mL at age 20 to approximately 80 ng/mL by age 60, representing more than a 60% reduction that correlates temporally with reduced wound healing capacity, collagen loss, and other markers of tissue aging. This documented decline provides the biological rationale for replenishment research and forms the foundation of GHK-Cu's role in aging biology research.

The age-related decline is documented across multiple published studies and correlates with the broader phenomenon of age-associated bioactive peptide decline seen in other compounds (NAD+, IGF-1, MOTS-c). The temporal correlation between declining plasma GHK-Cu and reduced tissue repair capacity gives research designs a clear hypothesis-driven structure: aging causes GHK-Cu scarcity, and restoring availability may address downstream tissue repair and gene expression effects that decline with age.

Research implications

The age-related decline hypothesis has driven substantial regenerative and dermatological research interest in GHK-Cu. Research designs investigating age-related skin changes, chronic non-healing wounds in older populations, hair follicle aging, and connective tissue deterioration frequently use GHK-Cu as either a research tool or a reference compound for age-related decline studies. For deeper coverage of GHK-Cu within aging research contexts, see Best Peptides for Anti-Aging Research: A Comparison Guide for Canadian Labs.

Current Research Applications

GHK-Cu research applications cluster into five primary categories — skin biology and dermal repair, wound healing (both acute and chronic), hair follicle research, gene expression profiling, and cancer research through the compound's documented tumor suppressor gene modulation. Each category exploits different aspects of GHK-Cu's dual-mechanism biology.

Skin biology and dermal repair

Skin research remains GHK-Cu's strongest published application category. A landmark clinical study by Leyden et al. applying GHK-Cu creams to thigh skin over 12 weeks measured collagen production increases via skin biopsy, with treated skin showing substantially higher collagen density than control samples. Additional research documents GHK-Cu effects on decorin synthesis, glycosaminoglycan production, elastin cross-linking, and dermal fibroblast function. The compound's characterization across dermatological research is more extensive than for nearly any other small peptide.

Wound healing research

Rodent wound models consistently report accelerated re-epithelialization, increased capillary density, and reduced inflammatory phase duration following GHK-Cu administration. Research designs investigating chronic non-healing wounds, diabetic ulcers, and post-surgical wound healing frequently use GHK-Cu as a reference compound. The combined effects on collagen synthesis, angiogenesis, and inflammatory modulation position GHK-Cu as a multi-mechanism wound repair research tool.

Hair follicle research

Hair follicle research documents GHK-Cu effects on follicle morphology, enlargement of follicle size, and extended anagen-phase (growth phase) signaling. These effects have driven consumer interest in GHK-Cu for hair loss applications (though such uses remain outside legitimate research supply frameworks), and continue to support active research into hair follicle biology and androgenetic alopecia models.

Gene expression profiling

GHK-Cu is uniquely positioned for transcriptomic research given its documented modulation of approximately 4,000 human genes. Research designs investigating broad gene expression programs — cellular aging profiles, DNA repair pathway activation, antioxidant response element (ARE) gene expression — use GHK-Cu as a reference compound. The 2018 Pickart and Margolina review in International Journal of Molecular Sciences consolidated much of this genomic characterization work.

Cancer and neurological research

Emerging research directions include GHK-Cu's characterization as a potent cancer gene suppressor (Hong et al. 2010 identified GHK as one of the most potent among 1,309 tested bioactive compounds) and its potential nervous system effects (Pickart, Vasquez-Soltero, and Margolina published a 2017 review in Brain Sciences on GHK-Cu effects on gene expression relevant to nervous system function and cognitive decline). Peer-reviewed GHK-Cu research is searchable through PubMed GHK-Cu research.

How GHK-Cu Fits Within Emerald Peptides' Catalog

GHK-Cu occupies a distinctive research niche within our catalog — the only compound targeting extracellular matrix remodeling and broad gene expression modulation, complementing rather than duplicating our metabolic, recovery, and longevity peptides. Understanding how GHK-Cu combines with other compounds clarifies its research applications.

GHK-Cu pairs naturally with tissue repair peptides in multi-mechanism research designs. In our Glow Stack, GHK-Cu combines with BPC-157 (vascular and cytoprotective activity) and TB-500 (cellular migration) for three-mechanism dermal and connective tissue research. Our KLOW Stack extends this to four mechanisms by adding KPV for anti-inflammatory modulation alongside the tissue repair and ECM remodeling mechanisms.

For research designs investigating how GHK-Cu combines with other regenerative peptides, see KLOW Stack vs Glow Stack vs Wolverine Stack: Which Research Peptide Stack Fits Your Research Design? For broader coverage of GHK-Cu's position among recovery research peptides, see Best Peptides for Recovery Research: A Comparison Guide for Canadian Labs.

Sourcing Considerations

Research-grade GHK-Cu should meet four sourcing criteria: ≥99% HPLC purity, mass spectrometry identity confirmation matching the ~403.9 Da theoretical molecular weight of the copper complex, batch-specific certificates of analysis, and Canadian domestic supply chain integrity. Because GHK-Cu is a copper-bound peptide (rather than a pure peptide), quality control is somewhat more complex than for simpler research peptides.

The copper binding is a critical quality control dimension. Legitimate GHK-Cu should show the stable copper complex on mass spectrometry analysis — not the uncomplexed GHK peptide or copper contamination as separate signals. Suppliers who provide MS spectra showing the intact copper complex demonstrate synthesis quality that suppliers providing only HPLC purity numbers cannot verify. For a broader framework on evaluating research peptide suppliers, see Emerald Peptides vs. Other Brands: 7 Standards That Separate Quality Research Peptide Suppliers. Our Recovery Collection covers GHK-Cu alongside related research peptides in the tissue repair category.

Frequently Asked Questions

What does GHK-Cu stand for?

GHK-Cu stands for the three amino acids that comprise the tripeptide — glycine (G), histidine (H), and lysine (K) — plus the copper ion (Cu) that binds to the peptide structure. The full chemical name is glycyl-L-histidyl-L-lysine copper. The compound is also known as copper tripeptide-1 (particularly in cosmetic product listings) and is naturally occurring in human blood plasma. It was first isolated and characterized by Dr. Loren Pickart in 1973.

What is GHK-Cu used for in research?

GHK-Cu is used primarily in five research application categories: skin biology and dermal repair research (where its collagen synthesis and ECM remodeling effects are central), wound healing research (both acute and chronic wound models), hair follicle research (documented effects on follicle morphology and anagen-phase signaling), gene expression profiling and transcriptomic research (given its modulation of approximately 4,000 human genes), and cancer research through its documented tumor suppressor gene modulation. Research designs investigating regenerative biology, dermatological aging, and broad gene expression programs use GHK-Cu as a reference compound.

How does GHK-Cu work?

GHK-Cu operates through two integrated mechanisms. First, direct gene expression modulation — the compound modulates expression of approximately 4,000 human genes at nanomolar concentrations, upregulating DNA repair, antioxidant response, and tissue remodeling genes while downregulating inflammatory and tumor progression genes. Second, controlled copper delivery — the copper ion is held tightly enough to remain stably bound during circulation and cellular uptake, then becomes bioavailable to copper-dependent enzymes (lysyl oxidase, superoxide dismutase, cytochrome c oxidase) at intracellular targets. Together, these mechanisms drive the compound's characterized effects on tissue repair, collagen synthesis, and gene expression profiles.

Why do GHK-Cu plasma levels decline with age?

Endogenous GHK-Cu plasma concentration declines from approximately 200 ng/mL at age 20 to approximately 80 ng/mL by age 60 — more than a 60% reduction. The mechanism underlying this decline involves reduced production from breakdown of larger collagen proteins and potentially altered clearance mechanisms in older tissues. The decline correlates temporally with reduced wound healing capacity, collagen loss, and other markers of tissue aging, forming the biological rationale for GHK-Cu replenishment research in aging biology contexts.

Is GHK-Cu approved for human use?

No. GHK-Cu is not approved by Health Canada or the FDA for any human therapeutic use as an injectable or systemic compound. However, GHK-Cu (as "copper tripeptide-1") appears in numerous topical cosmetic products that are marketed for skin care applications — these are regulated as cosmetics rather than therapeutics, and their regulatory status differs from injectable research use. Research-grade GHK-Cu remains available for laboratory research applications under research-use-only frameworks and is not sold for human consumption.

Where can researchers buy GHK-Cu in Canada?

Research-grade GHK-Cu is available through Canadian research peptide suppliers who meet HPLC purity, mass spectrometry identity, and batch documentation standards. Our GHK-Cu research peptide is supplied at ≥99% HPLC purity with MS-verified identity of the intact copper complex, batch-specific COAs, and fast domestic Canadian shipping. All vials are sold strictly for laboratory research use only. Researchers requiring multi-mechanism regenerative research kits containing GHK-Cu alongside other compounds can also source our Glow Stack or KLOW Stack.

⚠️ For research use only. Not intended for human or veterinary use. Not a drug, food, or supplement.